BRAIN Biotech and Syngenta form strategic cooperation applying synthetic biology to drive innovations in sustainable farming solutions
Combining expertise in synthetic biology and agricultural innovation to accelerate the development of next-generation biologicals.
KEY ANNOUNCEMENTS
Strategic cooperation to accelerate innovation in agricultural biologicals through synthetic biology.
BRAIN Biotech provides access to its proprietary BioArchive and expertise in advanced microbial strain development.
BRAIN Biotech AG, a leading provider of specialised enzymes and innovative biosolutions for industry, and Syngenta, a global leader in agricultural innovation, are joining forces to accelerate the development of biologicals.
The companies are strategically combining BRAIN Biotech’s scientific expertise in synthetic biology with Syngenta’s global leadership in biologicals to support the development of next-generation agricultural solutions and address key challenges in sustainable farming.
Advancing agricultural biologicals through collaboration
BRAIN Biotech will contribute its advanced microbial strain development capabilities to support Syngenta’s research initiatives aimed at expanding the potential of novel biologicals. These nature-inspired solutions are intended to complement traditional crop protection products and help enhance plant health, resilience and productivity.
“Partnering with a global leader like Syngenta underscores the importance of biological innovation for sustainable agriculture.”
Martin Langer
Executive Vice President, BRAIN Biotech
“We see this collaboration as a powerful way to combine our extensive industrial biotechnology toolset with Syngenta’s scale and field-driven insights to create solutions which positively impact farmers as well as the environment.”
Unlocking the potential of microbial diversity
BRAIN Biotech offers highly specialised microbiological services, including the identification and optimisation of microbial strains for the production of enzymes and biomolecules.
Its extensive portfolio of biotechnological methods and customer-oriented services supports the development of innovative, next-generation solutions and products. These capabilities are now brought together under its industrial biotechnology brand, BRAINBiocatalysts.
Customers will also have access to the proprietary BRAIN BioArchive, a collection of tens of thousands of unique microbial strains. This resource enables the identification and selection of specific strains tailored to individual application requirements.
BRAIN BioArchive
A proprietary collection of tens of thousands of unique microbial strains, providing a resource for identifying microorganisms tailored to specific industrial and agricultural applications.
“At Syngenta, we believe agricultural innovation unlocks the next-generation of sustainable farming solutions and are committed to working with partners who share the same vision.”
Jérôme Cassayre
Head of Biologicals Research, Syngenta
“We’re excited to work with BRAIN Biotech to push back the boundaries of science in agricultural biologicals.”
About BRAINBiocatalysts
BRAINBiocatalysts is the industrial biotechnology brand of the BRAIN Biotech Group. It brings together expertise in discovery, development, scale-up and manufacturing to deliver scalable bio-based solutions for complex challenges and specialised applications.
Its capabilities include enzyme discovery and development, microbial strain development, bioprocess development, application expertise and commercial manufacturing.
The brand brings together the capabilities of BRAIN Biotech AG, Biocatalysts Ltd., Breatec B.V., WeissBiotech GmbH and Biocatalysts Inc.
About BRAIN Biotech Group
The BRAIN Biotech Group develops and provides bio-based products and solutions for industry. Its activities are organised into two business segments: BRAINBiocatalysts, focused on specialty enzymes, microorganisms and ingredients, and BRAINBioIncubator, which focuses on research-intensive development projects and pharmaceuticals.
The group operates fermentation facilities in the UK, alongside additional production sites in continental Europe and the United States.
BRAIN Biotech AG has been listed on the Frankfurt Stock Exchange since February 2016. In fiscal year 2024/25, the group generated revenue of €49.6 million with approximately 280 employees.
Disclaimer
This press release contains forward-looking statements reflecting the current views, expectations and assumptions of BRAIN Biotech AG management. Such statements are based on currently available information and are subject to known and unknown risks and uncertainties. Actual results and future developments may differ materially from those expressed or implied. BRAIN Biotech AG undertakes no obligation to update or revise forward-looking statements.
BRAIN Biotech AG
Strategic Cooperation with Syngenta | November 2026
Leave a Reply